Krystal's 30% growth is mostly abroad; $400M buyback, eye readouts slip

Krystal Biotech, based in Pittsburgh, makes VYJUVEK, which it calls the first redosable gene therapy and the first genetic medicine approved in the United States, Europe and Japan for dystrophic epidermolysis bullosa.¹ The FDA label covers wounds in patients with that disease who carry mutations in the COL7A1 collagen gene.² The company estimates there are over 3,000 patients with the disease in the United States. Its own filing says its operating profit depends on continued sales of this one drug, and cumulative VYJUVEK sales since launch reached $1,093.3 million by September 30.³

Sales run through few hands. In 2025 about 75% of net product revenue came from a single US customer, and one customer held 61% of receivables at September 30.¹ Rivals exist: Abeona's Zevaskyn, an autologous gene therapy made from a patient's own cells, won FDA approval in 2025.²

Growth outside the US is recent. VYJUVEK launched in Germany in August 2025 and in France and Japan in October 2025, and in August 2026 the company still aimed to launch in Italy and Spain in the second half of 2026.¹ The US slowdown is not new either. In the second quarter, US sales fell to $91.6 million from $96.0 million a year earlier, and the company said growth came from Europe and Japan, partly offset by lower US sales.²

On October 15 Krystal reported early data for KB113, the low dose of its injected immunotherapy KB707, in skin cancers of patients with Gorlin syndrome: 69 of 83 tracked lesions showed some regression, but only 42 shrank by more than half and 8 by 90% or more.¹ Only three patients were treated. The study had no control group and the study's own investigator scored the results, so it is an early signal rather than proof.²

Chief executive Krish Krishnan, also a director and 10% holder, sold 25,000 shares in early September at prices from $354.54 to $366.5567, under a trading plan adopted a year earlier, and Suma Krishnan, President of R&D and also a 10% holder, sold another 25,000 shares the same day.¹ Director Dino Rossi filed to sell 25,000 shares on or about August 14, and his Form 4 shows open-market sales that left him with 50,000 shares.² In August and September the Chief Accounting Officer and the Head of International adopted new trading plans to sell up to 11,527 and 3,045 shares.³ In our price file the stock closed at $336.52 on September 15, as high as $351.13 on September 22 and as low as $311.49 on October 23. It last closed at $331.665 on October 30 and had not traded in a regular session since the filing.⁴

Third-quarter net product revenue was $127.3 million, up 30% from $97.8 million.¹ Europe brought in $23.3 million against $4.9 million a year earlier, and Japan, which had no sales then, added $8.8 million.² US sales rose 2.6% to $95.3 million from $92.9 million, so Europe and Japan supplied about 92% of the quarter's year-on-year gain.³

The nine-month figures are weaker for the US: US sales fell to $274.4 million from $277.1 million, while total sales grew 29% to $362.9 million. The company itself names lower US sales as a partial offset to growth.¹ There is one bright spot. Third-quarter US sales of $95.3 million were 4.0% above the second quarter's $91.6 million.² The US is still about 75% of third-quarter sales, so a flat US market limits how fast the whole company can grow.³

One pressure point sits on the balance sheet. Accrued rebates, money Krystal expects to owe payers, rose by $36.0 million since December to $94.2 million, and the company takes part in government rebate programs including Medicaid.¹ Nine-month provisions for rebates and other price deductions totaled $83.3 million, of which rebates were $73.8 million. Rising rebates would shrink the net price Krystal keeps per US sale, but the filing does not tie them to the US sales trend.²

Gross margin, the share of sales left after the cost of making the product, was 94%, down from 96%. Cost of goods rose 77%, which the company puts down partly to higher per-unit costs in Europe and Japan.¹ Operating income rose to $71.1 million from $41.4 million, a 56% margin on sales. Pre-tax income rose 67% to $80.1 million.²

Net income still fell 21% to $63.1 million, and diluted earnings per share fell to $2.05 from $2.66.¹ The reason is tax. Last year's quarter booked a $31.4 million tax benefit when the company released a valuation allowance, a one-time accounting reserve against tax savings, while this quarter carried $17.1 million of tax expense, or 21.3% of pre-tax income.²

Two other items shape the quality of the quarter. Selling and administrative costs fell 10% to $33.7 million, helped by a one-time $3.0 million insurance repayment of past legal bills; without it they would have been $36.7 million, still below last year's $37.6 million.¹ Stock pay, a non-cash cost, was $13.9 million in the quarter. Krystal's own spending guidance leaves stock pay out entirely, so its adjusted expense figures run below reported costs.²

The business produces real cash. Operating activities brought in $246.4 million in the nine-month period, against $123.4 million a year earlier, and after $11.7 million of equipment spending, free cash flow was $234.7 million.¹ Part of the jump is that the 2025 figure carried a $31.3 million final payment on the PeriphaGen legal settlement.² Another part is timing: accrued rebates that Krystal has booked but not yet paid rose $36.0 million in the nine months, and that build counts as operating cash until the rebates are paid.³

Cash, cash equivalents and investments totaled $1.19 billion at September 30, about $40 a share. The long-term part of the portfolio matures in one to two years.¹ The 10-K said the company has no outside borrowings, and total liabilities at September 30 were $150.5 million. With no debt, debt ratios and interest cover do not apply; instead, interest and other income added $9.0 million in the quarter.² Management says its cash will fund planned operations for at least the next 12 months.³

In October the board approved buying back up to $400 million of stock. At the October 30 close that is about 4% of the $9.8 billion market value and about 33% of cash and investments, and it would retire about 1.2 million shares at that price.¹ Management expects to buy opportunistically over the next two years, but the program has no expiration date and no duty to buy anything.² What holders give up is cash that could fund the pipeline, a trade-off the company's own release lists as a risk. Purchases may also carry a 1% federal excise tax.³

The buyback works against steady dilution from stock pay. At September 30 there were 1,998,707 options, 304,461 unvested restricted stock units and 43,536 performance units, about 2.35 million in all, or about 8% of the 29.6 million shares outstanding.¹ The equity plan's reserve also grows each year by 4% of outstanding shares.²

The pipeline news ran the other way. KB803 treats the eye complications of dystrophic epidermolysis bullosa, and IOLITE, its registrational trial, measures the change in days per month with corneal abrasion symptoms on the drug against placebo.¹ In August the company expected IOLITE top-line results before the end of 2026. Now it expects the last patient visit in February 2027, with results shortly after, having replaced two patients who withdrew.²

KB801, for neurotrophic keratitis, a corneal disease, is in a registrational trial called EMERALD-1. In August the company expected to finish enrolling about 60 patients before the end of 2026.¹ Now enrollment is slower than planned despite 22 active US sites, and both full enrollment and top-line results are set for 2027.² Interim results for KB407, a cystic fibrosis candidate, also moved to the first half of 2027, and the Italy launch slid from the second half of 2026 to early 2027. KB111, for Hailey-Hailey disease, was to start a registrational study in the second half of 2026 under the 10-K plan; by the August update that start had already moved to 2027.³

On the other side, the pricing deals that set what European governments pay are falling into place. Germany finished in October 2026 and Italy is also done, while France is expected to run until at least 2027.¹ A pricing decision in Spain is expected before the end of the year.²

Two legal matters stay open. The Justice Department subpoenaed the company and some employees about its sponsored genetic testing program for VYJUVEK, and the company says it cannot estimate any possible loss.¹ Separately, Jonathan Forman sued in May 2026, seeking to be named an inventor on patents he says cover KB407.²

The company's own goals, which are plans and not results, include KB111 interim results before year end and an FDA meeting on KB111 in the first quarter of 2027.¹ It also plans a Switzerland marketing application before year end and about 70 patients in the KB707 chemotherapy cohort by mid-2027.² It cut its 2026 guidance for combined research and selling costs, excluding stock pay, to $155 million to $165 million from $175 million to $195 million.³

At $331.665 a share, the $9.8 billion market value is about 19 times the third quarter's sales multiplied by four. Taking out $1.19 billion of cash and investments leaves an enterprise value of about $8.6 billion, or 30.3 times the third quarter's operating income multiplied by four.¹ Those are our own run-rate sums, not company figures, and they price in growth that a flat US market does not supply today.²

The bull case: Krystal has no borrowings, a 94% gross margin, $234.7 million of nine-month free cash flow and $1.19 billion of cash and investments, and it is now returning cash through a buyback.¹ Europe grew to $23.3 million in the third quarter, Germany and Italy have prices, and US sales rose 4.0% from the second quarter.² The lower spending guidance mostly matches what has already been spent: $117.6 million through nine months excluding stock pay leaves $37.4 million to $47.4 million for the fourth quarter, at or above the third quarter's $34.7 million, so it does not by itself point to wider margins.³

The bear case, strongest point first. The US, about 75% of sales, fell in the nine-month figures, and accrued rebates rose $36.0 million, though the filings do not say whether that reflects a higher rebate rate or slower payment.¹ Second, the two eye trials meant to widen the franchise in 2026 have both slipped into 2027, and the KB113 data come from three patients. Third, the tax benefit that lifted 2025 will not repeat, and the Justice Department inquiry carries no loss estimate.²

Our call is that the stock holds up in the week after the results, with the buyback in place and cash near $40 a share. It is wrong if the market treats the stalled US and the trial delays as a reason to reprice the stock sharply lower.¹ Longer term, the test is fourth-quarter US sales against the third quarter's $95.3 million, due with the full-year report, and IOLITE results after the February 2027 last patient visit.²

The 10-Q names lower US sales as an offset to growth in the nine-month figures but gives no reason, and we found no transcript of the November 2 call. Whether it reflects fewer patients refilling, higher rebates or something else is open.

The filings give the $400 million authorization but no purchases so far, no average price paid and no share count bought.

The filings give total rebate accruals but no rebate rate by country, so how much of the rise falls on US sales is not known.